Horizon Therapeutics PLC (HZNP)
| Market Cap | 21.07B |
| Revenue (ttm) | 2.20B |
| Net Income (ttm) | 389.80M |
| Shares Out | 203.97M |
| EPS (ttm) | 3.61 |
| PE Ratio | 25.08 |
| Forward PE | 19.80 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | February 25 |
| Last Price | $90.59 |
| Previous Close | $95.48 |
| Change ($) | -4.90 |
| Change (%) | -5.13% |
| Day's Open | 94.59 |
| Day's Range | 89.77 - 94.99 |
| Day's Volume | 3,547,610 |
| 52-Week Range | 23.81 - 96.54 |
Horizon (HZNP) beats earnings and sales estimates in the fourth quarter of 2020.
The biopharmaceutical company released its latest quarterly update.
Horizon Therapeutics (HZNP) delivered earnings and revenue surprises of 21.90% and 7.36%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for th...
Shares of Horizon Therapeutics (NASDAQ:HZNP) remained unaffected after the company reported Q4 results. Quarterly Results Earnings per share rose 128.57% over the past year to $1.28, which bea...
DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc Reports Record Fourth-Quarter and Full-Year 2020 Financial Results; Announces Full-Year 2021 Guidance
DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics announced results of a new Thyroid Eye Disease (TED) quality of life assessment presented at the NANOS Annual Meeting.
Paulson & Co., the firm led by John Paulson (Trades, Portfolio), disclosed this week that its top five buys during the fourth quarter of 2020 were in Horizon Therapeutics PLC (NASDAQ:HZNP), Ba...
Horizon Therapeutics (HZNP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NEW YORK--(BUSINESS WIRE)--Horizon Therapeutics expands partnership with Medidata to speed clinical trial start-up and completion, using a broad range of technology solutions.
DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) announced today that its fourth-quarter and full-year 2020 financial results will be released on Wednesday, Feb. 24, 2021. Foll...
Horizon Therapeutics (HZNP) is set to buy Viela Bio for $3.05 billion to expand its pipeline and accelerate growth.
Horizon Pharma saw an improvement in its IBD SmartSelect Composite Rating Monday, from 94 to 96. The post Horizon Pharma Sees Rising Composite Rating To 96 appeared first on Investor's Busines...
Horizon Therapeutics PLC (NASDAQ: HZNP), a rare and rheumatic diseases drug company, announced a multibillion-dollar deal Monday to snap up Viela Bio Inc (NASDAQ: VIE). What Happened: Horizon ...
Horizon Therapeutics Plc said Monday it has agreed to acquire Viela Bio Inc. for $53 a share in cash, or an equity value of about $3.05 billion. The deal is expected to close by the end of the...
DUBLIN & GAITHERSBURG, Md.--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) and Viela Bio, Inc. (Nasdaq: VIE) today announced the companies have entered into a definitive agreement un...
Growth stocks are a great way to make money. Here are seven of the stronger names in the S&P 500's hottest sectors for investors to consider.
These are the healthcare stocks with the best value, fastest growth, and most momentum for February 2021.
Horizon (HZNP) provides 2020 preliminary financial results and updates on its key drugs.
DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced updates on its 2020 financial results, TEPEZZA supply and new KRYSTEXXA trials. “Amid the most challenging envi...
Horizon Therapeutics has morphed into a biotech star due to its new compound Tepezza. Tepezza is approved for the treatment of thyroid eye disease otherwise known as TED.
These are the healthcare stocks with the best value, fastest growth, and most momentum for January 2021.
DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the Company will participate in the 39th Annual J.P. Morgan Healthcare Conference. Tim Walbert, chairman, ...
DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) announced that it expects a short-term disruption in TEPEZZA (teprotumumab-trbw) supply as a result of recent government-mandat...
Horizon Therapeutics PLC (NASDAQ:HZNP) and Gilead Sciences Inc (NASDAQ:GILD) are two contrasting stocks from the drug manufacturing industry, in my opinion. What they share is a price that has...
These are the pharmaceutical stocks with the best value, fastest growth, and most momentum for Q1 2021.
LAKE FOREST, Ill.--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it has provided $500,000 in scholarships to Lake Forest College and created a $500,000 Horizon ...
Horizon Therapeutics (HZNP) reported earnings 30 days ago. What's next for the stock?
DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) announced today that it has been named to Great Place to Work's 2020 Best Workplaces for Parents list, which highlights compani...
LAKE FOREST, Ill.--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) announced today that it has provided $1.2 million in additional funding to U.S and international organizations to su...
Horizon Therapeutics (HZNP) expects continued strong growth for Krystexxa and Tepezza in 2021. It is making efforts to expand the label for its marketed drugs.
DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the Company will participate in the following conferences in December: 2020 Evercore ISI HealthCONx Confer...
DUBLIN & SAN DIEGO--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) and Halozyme Therapeutics, Inc. (Nasdaq: HALO) today announced a global collaboration and license agreement that gi...
Let's see if Horizon Therapeutics (HZNP) stock is a good choice for value-oriented investors right now from multiple angles.
DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) has been named to the National Association for Business Resources' 2020 list of Best and Brightest Companies to Work For in the...
Most experienced investors are well aware of the major indexes that compose the equity markets.
DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that Tim Walbert, chairman, president and chief executive officer, has been honored with the 2020 RARE Champion...
Horizon Therapeutics CEO On Success Of Key Drug Tepezza, Acquisition Plans
Horizon Therapeutics on Monday reported a solid quarter with big beats on the top and bottom lines and raised its guidance, thanks in large part to its thyroid eye disease drug Tepezza, which ...
Horizon (HZNP) beats both earnings and sales estimates in the third quarter of 2020.
DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced data from the first randomized controlled clinical trial (RCT) of KRYSTEXXA (pegloticase injection) concomitant...
Horizon Therapeutics PLC (HZNP) CEO Timothy Walbert on Q3 2020 Results - Earnings Call Transcript
Horizon Therapeutics posted third-quarter earnings and sales that easily topped Wall Street expectations and the maker of drugs to treat rare diseases hiked its outlook, but HZNP stock fell. T...
Horizon Therapeutics (HZNP) delivered earnings and revenue surprises of 74.00% and 13.88%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for ...
DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc Reports Record Third-Quarter 2020 Results and Increases Full-Year Net Sales and Adjusted EBITDA Guidance
DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that Karin Rosén, M.D., Ph.D., has joined the company as executive vice president, research and development and...
DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it has been named one of the Chicago Tribune's Top Workplaces 2020, ranking number two out of other midsiz...
SEATTLE, Oct. 29, 2020 /PRNewswire/ -- AGC Biologics, a leading global biopharmaceutical Contract Development and Manufacturing Organization (CDMO), announced that its partnership with Horizon...
DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the first patient has been enrolled in the Infusion Duration Study to Assess Tolerability of Pegloticase A...
Horizon (HZNP) will provide updates on its marketed drugs, earnings and other pipeline candidates when it releases third-quarter 2020 results on Nov 2.
At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in ( Recession is Imminent: We Need A Travel ...
Horizon Therapeutics (HZNP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
About HZNP
Horizon Therapeutics Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing of medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. Its orphan and rheumatology marketed medicines include KRYSTEXXA, a medicine for the treatment of uncontrolled gout; RAVICTI for use as a nitrogen-binding agent for chronic management of adult and pediatric patients; PROCYSBI for nephropathic cystinosis, a rare and life-threatening metabolic disor... [Read more...]
| Industry Drug Manufacturers-General | IPO Date Jul 28, 2011 |
| CEO Timothy P. Walbert | Employees 1,275 |
| Stock Exchange NASDAQ | Ticker Symbol HZNP |
Financial Performance
In 2020, HZNP's revenue was $2.20 billion, an increase of 69.26% compared to the previous year's $1.30 billion. Earnings were $389.80 million, a decrease of -31.98%.
Analyst Forecasts
According to 11 analysts, the average rating for HZNP stock is "Buy." The 12-month stock price forecast is 110.33, which is an increase of 21.80% from the latest price.